Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions
Reduce the dose in patients with renal impairment; if on hemodialysis, administer afterward; common adverse effects include headache, fatigue, dizziness, and nausea; may elevate liver enzyme levels; may cause lactic acidosis; severe acute exacerbations of HBV infection may occur in patients who discontinue anti-HBV therapy
Dosing
Adult
Treatment for nucleoside for naive patentes: 0.5 mg each day PO 2 h before meals or 2h afre meals, on an empty stomach
CrCl 30-49 mL/min: 0.25 mg PO qd
CrCl 10-29 mL/min: 0.15 mg PO qd
CrCl <10 mL/min: 0.05 mg PO qd
Receiving lamivudine or lamivudine resistance: 1 mg PO qd 2 h before meals or 2h afre meals, on an empty stomach